Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer

Reproductive Sciences

Volumn 22, Issue 1, 2015, Pages 38-46

  Belotte, Jimmy ^a   Fletcher, Nicole M ^a   Alexis, Mitchell ^a   Morris, Robert T ^a   Munkarah, Adnan R ^b   Diamond, Michael P ^c   Saed, Ghassan M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

overall survival; serous epithelial ovarian cancer; Sox2 amplification

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; POU5F1 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ARTICLE; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DATABASES, GENETIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; NANOG HOMEOBOX PROTEIN; NEOPLASMS, GLANDULAR AND EPITHELIAL; OCTAMER TRANSCRIPTION FACTOR-3; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; SOXB1 TRANSCRIPTION FACTORS; TIME FACTORS;

EID: 84919667222     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114542021     Document Type: Article

References (78)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 ; 63 ((1)). 11-30
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004 ; 351 ((24)). 2519-2529
3. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003 ; 138 ((7)). 560-570
4. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol. 1988 ; 128 ((3)). 456-466
5. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol. 1994 ; 55 ((3 pt 2)). S15 - S19
6. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 1993 ; 270 ((23)). 2813-2818
7. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 2003 ; 1: 73
8. Minegishi K, Tanaka M, Nishimura O, et al. Reactive oxygen species mediate leukocyte-endothelium interactions in prostaglandin F2alpha-induced luteolysis in rats. Am J Physiol Endocrinol Metab. 2002 ; 283 ((6)). E1308 - E1315
9. Shirai F, Kawaguchi M, Yutsudo M, Dohi Y. Human peripheral blood polymorphonuclear leukocytes at the ovulatory period are in an activated state. Mol Cell Endocrinol. 2002 ; 196 ((1-2)). 21-28
10. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. J Soc Gynecol Investig. 2001 ; 8 ((1 suppl proceedings)). S40 - S42
11. Guo R, Wu Q, Liu F, Wang Y. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep. 2011 ; 25 ((1)). 141-146
12. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010 ; 5 ((1)). e8960
13. Katoh M, Katoh M. Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int J Oncol. 2007 ; 31 ((2)). 461-466
14. Lu Y, Futtner C, Rock JR, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One. 2010 ; 5 ((6)). e11022
15. Tani Y, Akiyama Y, Fukamachi H, Yanagihara K, Yuasa Y. Transcription factor SOX2 up-regulates stomach-specific pepsinogen a gene expression. J Cancer Res Clin Oncol. 2007 ; 133 ((4)). 263-269
16. Zhong X, Li N, Liang S, Huang Q, Coukos G, Zhang L. Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem. 2010 ; 285 ((53)). 41961-41971
17. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008 ; 68 ((11)). 4311-4320
18. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 ; 414 ((6859)). 105-111
19. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997 ; 3 ((7)). 730-737
20. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003 ; 63 ((18)). 5821-5828
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003 ; 100 ((7)). 3983-3988
22. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007 ; 445 ((7123)). 106-110
23. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007 ; 67 ((3)). 1030-1037
24. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998 ; 282 ((5391)). 1145-1147
25. Casati A, Frascoli M, Traggiai E, Proietti M, Schenk U, Grassi F. Cell-autonomous regulation of hematopoietic stem cell cycling activity by ATP. Cell Death Differ. 2011 ; 18 ((3)). 396-404
26. Abdelalim EM, Tooyama I. NPR-A regulates self-renewal and pluripotency of embryonic stem cells. Cell Death Dis. 2011 ; 2: e127
27. Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2011 ; 2: e204
28. Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003 ; 113 ((5)). 643-655
29. Molofsky AV, Pardal R, Morrison SJ. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol. 2004 ; 16 ((6)). 700-707
30. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 ; 131 ((5)). 861-872
31. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 ; 126 ((4)). 663-676
32. Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med. 2000 ; 6 ((11)). 1278-1281
33. Karanu FN, Murdoch B, Gallacher L, et al. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med. 2000 ; 192 ((9)). 1365-1372
34. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol. 2001 ; 2 ((2)). 172-180
35. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982 ; 31 ((1)). 99-109
36. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997 ; 11 ((24)). 3286-3305
37. Reya T, O'Riordan M, Okamura R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity. 2000 ; 13 ((1)). 15-24
38. Austin TW, Solar GP, Ziegler FC, Liem L, Matthews W. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood. 1997 ; 89 ((10)). 3624-3635
39. Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood. 1998 ; 92 ((9)). 3189-3202
40. Daheron L, Opitz SL, Zaehres H, et al. LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells. 2004 ; 22 ((5)). 770-778
41. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science. 2002 ; 298 ((5593)). 601-604
42. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 ; 474 ((7353)). 609-615
43. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 ; 455 ((7216)). 1061-1068
44. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 ; 17 ((1)). 98-110
45. Wang XV, Verhaak RG, Purdom E, Spellman PT, Speed TP. Unifying gene expression measures from multiple platforms using factor analysis. PLoS One. 2011 ; 6 ((3)). e17691
46. Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 ; 123 ((1)). 517-525
47. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013 ; 6 (269). l1
48. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science. 2004 ; 305 ((5683)). 525-528
49. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004 ; 36 ((9)). 949-951
50. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006 ; 444 ((7118)). 444-454
51. Wong KK, deLeeuw RJ, Dosanjh NS, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet. 2007 ; 80 ((1)). 91-104
52. Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 2009 ; 460 ((7251)). 118-122
53. Ma L, Lai D, Liu T, Cheng W, Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai). 2010 ; 42 ((9)). 593-602
54. Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol. 2008 ; 317 ((1)). 296-309
55. Zhang J, Chang DY, Mercado-Uribe I, Liu J. Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. Hum Pathol. 2012 ; 43 ((9)). 1405-1412
56. Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H. Expression of Sox2 in human ovarian epithelial carcinoma. J Cancer Res Clin Oncol. 2011 ; 137 ((1)). 131-137
57. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 2010 ; 29 ((14)). 2153-2159
58. Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY, Cheung AN. Dysregulated stemness-related genes in gynecological malignancies. Histol Histopathol. 2012 ; 27 ((9)). 1121-1130
59. Liang D, Ma Y, Liu J, et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer. 2012 ; 12: 201
60. Kregel S, Kiriluk KJ, Rosen AM, et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013 ; 8 ((1)). e53701
61. Gubbay J, Collignon J, Koopman P, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature. 1990 ; 346 ((6281)). 245-250
62. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000 ; 227 ((2)). 239-255
63. Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev. 1997 ; 7 ((3)). 338-344
64. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 1999 ; 27 ((6)). 1409-1420
65. Soullier S, Jay P, Poulat F, Vanacker JM, Berta P, Laudet V. Diversification pattern of the HMG and SOX family members during evolution. J Mol Evol. 1999 ; 48 ((5)). 517-527
66. Rizzino A. Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med. 2009 ; 1 ((2)). 228-236
67. Johansson H, Simonsson S. Core transcription factors, Oct4, Sox2 and Nanog, individually form complexes with nucleophosmin (Npm1) to control embryonic stem (ES) cell fate determination. Aging (Albany NY). 2010 ; 2 ((11)). 815-822
68. Zhang X, Lu F, Wang J, et al. Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. Cell Rep. 2013 ; 5 ((2)). 445-457
69. Velcheti V, Schalper K, Yao X, et al. High SOX2 levels predict better outcome in non-small cell lung carcinomas. PLoS One. 2013 ; 8 ((4)). e61427
70. Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011 ; 24 ((7)). 944-953
71. Abbas HA, Pant V, Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle. 2011 ; 10 ((19)). 3257-3262
72. Lin T, Chao C, Saito S, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol. 2005 ; 7 ((2)). 165-171
73. Xu Y. A new role for p53 in maintaining genetic stability in embryonic stem cells. Cell Cycle. 2005 ; 4 ((3)). 363-364
74. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000 ; 283 ((17)). 2260-2265
75. Garg K, Levine DA, Olvera N, et al. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol. 2013 ; 37 ((1)). 138-146
76. Lacour RA, Westin SN, Meyer LA, et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol. 2011 ; 121 ((2)). 358-363
77. Liu J, Cristea MC, Frankel P, et al. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 2012 ; 205 ((1-2)). 34-41
78. Liu G, Yang D, Sun Y, et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics. 2012 ; 13 ((13)). 1523-1535